je.st
news
Tag: inhibitor
Boston Biomedical Announces Clinical Data Presentation Of Its Cancer Stem Cell Inhibitor Programs
2014-06-16 19:56:43| Logistics - Topix.net
Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by the company.
Tags: data
cell
programs
presentation
New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
2014-03-05 18:15:00| Merck.com - Product News
Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today that in a new 96-week, open-label AIDS Clinical Trials Group (ACTG) study designed to compare three different NNRTI-sparing HIV regimens in treatment-nave patients one containing Mercks twice-daily ISENTRESS (raltegravir) and two containing different once-daily ritonavir-boosted protease inhibitors, atazanavir and darunavir -- all three regimens achieved high and equivalent levels of efficacy, as measured by time to virologic failure (V Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
results
large
study
Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
2014-03-05 04:59:35| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, recently announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Tags: data
presented
conference
21st
Verastem Issued Japanese Patent On Dual mTORC1/2 And PI3K Inhibitor VS-5584
2014-02-05 07:02:35| drugdiscoveryonline News Articles
Verastem, Inc. focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, recently announced that it has been issued a patent by the Japanese Patent Office (JPO) for the company’s small molecule dual inhibitor of mTORC1/2 and PI3K VS-5584
Tags: japanese
issued
dual
patent
Oxide inhibitor
2014-01-15 16:13:00| Electrical Construction & Maintenance
Available in bottles, tubes, and packets, De-Ox oxide inhibitor comes in three formulas read more